Piramal Pharma Share Price
Small Cap | Pharmaceuticals and health care | NSE: PPLPHARMA | BSE: 543635
₹204.35 -16.75 (-7.58 %)
Last Updated: 11 Feb 2025 04:01 PM
Overview
Open (₹) 220.15
High (₹) 221.50
Low (₹) 203.10
Prev. Close (₹) 221.10
Volume 2,03,297
VWAP (₹) 228.16
ROCE (%) 5.76
Industry P/E 47.86
TTM P/E 704.66
P/B Ratio 3.42
Market Cap (₹) Cr.27,082.38
Dividend Yield (%)0.05
EPS (₹) 0.14
ROE0.23%
Sales Growth (%) 15.39
Profit Growth (%)-82.69
Day Range
221.50221.50
52 Week Range
114.45307.85
Historical Returns
Returns (6M)
12.25 %
Returns (1Y)
52.96 %
Returns (3Y)
9.12 %
Returns (5Y)
9.12 %
Returns (6M)
12.25 %
Returns (1Y)
52.96 %
Returns (3Y)
9.12 %
Returns (5Y)
9.12 %
SWOT Analysis
- Effectively using its capital to generate profits - ROCE improved in the last year
- Book value per share improving over the last 2 years
- Efficient in managing Assets to generate Profits - ROA improved since last year
- Increasing Annual Revenue for Past 2 Years
- Positive ROC (9) indicates upward momentum.
Technicals![info_icon](/img/icons/info_icon.svg)
Technical Rating
RSI 54.57
MFI 54.15
ATR 12.39
Commodity Channel Index -82.88
ROC125 22.53
ROC21 -7.64
Williams %R -53.29
Resistance & Support![info_icon](/img/icons/info_icon.svg)
Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
---|---|---|---|---|---|---|---|
Current | 231.69 | 236.82 | 240.64 | 227.87 | 222.74 | 218.92 | 213.79 |
Week Ago | 237.49 | 242.07 | 245.34 | 234.22 | 229.64 | 226.37 | 221.79 |
Month Ago | 253.26 | 256.18 | 258.96 | 250.48 | 247.56 | 244.78 | 241.86 |
EMA & SMA![info_icon](/img/icons/info_icon.svg)
204.35
Current Price
Bullish Moving Averages
1
Bearish Moving Averages
19
5 Day 229.89
9 Day 232.71
10 Day 227.79
12 Day 231.68
14 Day 232.74
20 Day 232.74
26 Day 237.66
50 Day 247.47
100 Day 244.02
200 Day 204.35
Deals & Announcements
Bulk and Block Deals
Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
---|---|---|---|---|---|---|
EAST BRIDGE CAPITAL MASTER FUND LIMITED | block | Sell | 31 Oct, 2023 | ₹102.80 | 3,36,43,099 | BSE |
EAST BRIDGE CAPITAL MASTER FUND I LIMITED | block | Buy | 31 Oct, 2023 | ₹102.80 | 3,36,43,099 | BSE |
EAST BRIDGE CAPITAL MASTER FUND LIMITED | bulk | Sell | 31 Oct, 2023 | ₹102.80 | 3,36,43,099 | BSE |
EAST BRIDGE CAPITAL MASTER FUND I LIMITED | bulk | Buy | 31 Oct, 2023 | ₹102.80 | 3,36,43,099 | BSE |
ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 03 Nov, 2022 | ₹166.95 | 40,50,700 | BSE |
ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 03 Nov, 2022 | ₹166.95 | 40,50,700 | BSE |
Insider Trading
Corporate Actions
Announcement Date | Subject | Ex - Date | Record Date |
---|---|---|---|
10 May, 2024 | Rs.0.1100 per share(1.1%)Final Dividend | 12 Jul, 2024 | 12 Jul, 2024 |
08 Feb, 2023 | Rights issue of equity shares of Rs. 10/- in the ratio of 5:46 @ premium of Rs. 71/-. | 02 Aug, 2023 | 02 Aug, 2023 |
Announcements
Date | Source | Detail |
---|---|---|
31 Jan, 2025 | NSE India | Piramal Pharma Limited has informed the Exchange about Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Extension of timeline communicated for sale of Company s Unit situated at Thane |
31 Jan, 2025 | BSE India | Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Extension of timeline communicated for sale of Company''s Unit situated at Thane. |
30 Jan, 2025 | BSE India | Transcript of Conference call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024 |
30 Jan, 2025 | NSE India | Piramal Pharma Limited has informed the Exchange about Transcript |
30 Jan, 2025 | BSE India | Transcript of Conference Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2024 |
29 Jan, 2025 | NSE India | Piramal Pharma Limited has informed the Exchange about Link of Recording |
29 Jan, 2025 | BSE India | Audio Recording of Conference Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2024 |
29 Jan, 2025 | NSE India | Piramal Pharma Limited has informed the Exchange about Giving guarantees/indemnity/ becoming a surety for third party |
29 Jan, 2025 | BSE India | Intimation under Regulation 30 of The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (\SEBI Listing Regulations\) - Issuance of Corporate Guarantee. |
28 Jan, 2025 | NSE India | Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024 |
Board Meetings
Purpose | Details | Meeting Date | Broadcast Date |
---|---|---|---|
Quarterly Results | -- | 14 Jan, 2025 | 28 Jan, 2025 |
Quarterly Results | -- | 15 Oct, 2024 | 23 Oct, 2024 |
Quarterly Results | -- | 16 Jul, 2024 | 26 Jul, 2024 |
Audited Results & Final Dividend | -- | 02 May, 2024 | 10 May, 2024 |
Quarterly Results | -- | 18 Jan, 2024 | 30 Jan, 2024 |
Quarterly Results | -- | 19 Oct, 2023 | 27 Oct, 2023 |
Quarterly Results | -- | 31 Jul, 2023 | 03 Aug, 2023 |
Audited Results | -- | 19 May, 2023 | 24 May, 2023 |
Quarterly Results & Rights issue | -- | 07 Feb, 2023 | 08 Feb, 2023 |
Quarterly Results | -- | 02 Nov, 2022 | 08 Nov, 2022 |
Share Holding Pattern
Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
---|
About Piramal Pharma
Piramal Pharma is a Public Limited Listed company incorporated on 04/03/2020 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is U24297MH2020PLC338592 and registration number is 338592. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 4390.11 Cr. and Equity Capital is Rs. 1322.95 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Piramal Ajay Group
Founded
2020
Managing Director
-- --
NSE Symbol
PPLPHARMA
Piramal Pharma Management
Name | Designation |
---|---|
Mrs. Nandini Piramal | Chairperson |
Mr. Vivek Valsaraj | Executive Director & CFO |
Mr. Peter DeYoung | Executive Director |
Mr. Neeraj Bharadwaj | Non Executive Director |
Ms. Vibha Paul Rishi | Independent Director |
Mr. Jairaj Purandare | Independent Director |
Mr. Peter Stevenson | Independent Director |
Mr. S Ramadorai | Independent Director |
Mr. Sridhar Gorthi | Independent Director |
Peer Comparison
Stocks | Market Cap | Market Price | 52 Week Low-High |
---|---|---|---|
SunPhrmInds | ₹4,46,576.22 | ₹1,699.75 ₹1,732.10(-1.87%) | ₹1,249.800 - ₹1,960.200 |
Divis Labora | ₹1,56,123.40 | ₹5,946.75 ₹5,938.80(0.13%) | ₹3,350.050 - ₹6,448.750 |
Cipla | ₹1,21,675.13 | ₹1,453.15 ₹1,458.85(-0.39%) | ₹1,240.700 - ₹1,702.000 |
ManKind Phar | ₹1,18,478.90 | ₹2,450.30 ₹2,502.05(-2.07%) | ₹1,910.100 - ₹3,050.000 |
DrReddysLab | ₹1,15,939.04 | ₹1,209.80 ₹1,220.95(-0.91%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Piramal Pharma
What is the share price of Piramal Pharma?
The share price of Piramal Pharma on 11 Feb, 2025 is ₹ 204.35.
What is 52W high and 52W low share price of Piramal Pharma?
The highest and lowest 52W share prices of Piramal Pharma are ₹ 307.850 and ₹ 114.450
What is the market cap of Piramal Pharma?
The market capitalization of Piramal Pharma as of 11 Feb, 2025 is ₹ 27,082.38 Crores
What is the P/E ratio of Piramal Pharma?
The current P/E ratio of Piramal Pharma as of 11 Feb, 2025 is 47.86
What is the PB ratio of Piramal Pharma?
The PB ratio of Piramal Pharma as of 11 Feb, 2025 is 3.42
Top Gainers
948IHFL26I
IBHFL NCD186
₹845
₹705 (0.2%)
GREAVESCOT
Greaves
₹281.85
₹234.9 (0.2%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.2%)
CAPRO
Caprola.Chem
₹62.4
₹52 (0.2%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.1%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.1%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0%)